In stroke models where the thrombolytic therapy of tissue plasminogen activator (tPA) is given, APC improves barrier function and blocks the complication of hemorrhage by inhibiting the activity of matrix metalloproteinase-9 [29, 93], which proteolytically degrades the vascular basement membrane and proteins associated with the blood-brain barrier [94]. Here, MMP9 is linked to Stroke.